With great honor and pleasure, I, as the inaugural Co-Editor-in-Chief, would like to introduce you a newly launched peer-reviewed academic journal, the Health Decision. This is a brand-new journal in the Asia-Pacific region to promote value stories and evidence use in health decision-making and bring academic exchange among scholars.
As one of the pioneers in introducing Pharmacoeconomics into Chinese universities and scientific institutes, I have devoted myself for the past 20 years to the development and promotion of this subject in China, and I am lucky to witness its application in the Chinese national reimbursement drug listing (NRDL) since 5 years ago. I deeply realized that customized evidence developed from the local setting is of increasing need and importance for a country’s health decision-making from the individual level to the national. The evidence we need is not only for drug listing but also for more general decisions including clinical practice, public health programs, health services, and other relevant policies. Health Decision emerges against the backdrop of a more complete healthcare system development in the Asia-Pacific region. There is a growing need for gap-bridging of healthcare research and evidence-based decision-making in a variety of policy scenarios. Meanwhile, more efforts are needed to develop potential evidence-use for stimulating discussion in the academic community and informing value-based decision-making.
Health Decision is the first journal of its kind in the Asian- Pacific region that collects evidence in Pharmacoeconomics, health technology assessment, comparative-effectiveness research, value assessment framework, patient-reported outcomes, pharmacoepidemiology, public health, clinical pharmacy, medical insurance, health ser vices, and policy forming, evaluation and implementation. Health Decision welcomes researchers from multidisciplinary backgrounds to submit any of their most recent evidence, including but not limited to the following forms: original articles, reviews, case studies, letters, and comments. We especially encourage high-quality researches on traditional Chinese medicine. Health care policymakers, clinicians, pharmacists, economists, scholars, and anyone interested in health decisions are welcome to communicate on this platform.
I am honored to make the presence of this journal on behalf of the Co-Editors-in-Chief, as well as the editorial board made of young experts from the frontline of health science research and health decision-making from mainland China, Hong Kong, Macau, Taiwan, Singapore, the United States, and Europe, who will jointly drive the development of health decision-making in the Asia-Pacific region for the upcoming decades. I strongly believe that this new journal can become a high-quality one with strict rules both in a scientific way and in its presentation. I also hope that the journal can provide a freely-built platform for reliable information and communication with the efforts of all parties. We are looking forward to your enrollment and hope to see your researches on our page!
DECLARATIONS
Conflict of Interest
Aixia Ma is the Co-Editor-in-Chief of the journal. This is the Inaugural Editorial for the journal.
